|
|
| Line 3: |
Line 3: |
| | <StructureSection load='6p4y' size='340' side='right'caption='[[6p4y]], [[Resolution|resolution]] 1.80Å' scene=''> | | <StructureSection load='6p4y' size='340' side='right'caption='[[6p4y]], [[Resolution|resolution]] 1.80Å' scene=''> |
| | == Structural highlights == | | == Structural highlights == |
| - | <table><tr><td colspan='2'>[[6p4y]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Mus_musculus Mus musculus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6P4Y OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6P4Y FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[6p4y]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Mus_musculus Mus musculus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6P4Y OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6P4Y FirstGlance]. <br> |
| - | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6p4y FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6p4y OCA], [http://pdbe.org/6p4y PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6p4y RCSB], [http://www.ebi.ac.uk/pdbsum/6p4y PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6p4y ProSAT]</span></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.799Å</td></tr> |
| | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6p4y FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6p4y OCA], [https://pdbe.org/6p4y PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6p4y RCSB], [https://www.ebi.ac.uk/pdbsum/6p4y PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6p4y ProSAT]</span></td></tr> |
| | </table> | | </table> |
| | <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| Line 15: |
Line 16: |
| | </div> | | </div> |
| | <div class="pdbe-citations 6p4y" style="background-color:#fffaf0;"></div> | | <div class="pdbe-citations 6p4y" style="background-color:#fffaf0;"></div> |
| | + | |
| | + | ==See Also== |
| | + | *[[Monoclonal Antibodies 3D structures|Monoclonal Antibodies 3D structures]] |
| | == References == | | == References == |
| | <references/> | | <references/> |
| Line 21: |
Line 25: |
| | [[Category: Large Structures]] | | [[Category: Large Structures]] |
| | [[Category: Mus musculus]] | | [[Category: Mus musculus]] |
| - | [[Category: Kashi, L]] | + | [[Category: Kashi L]] |
| - | [[Category: Kohnhorst, C L]] | + | [[Category: Kohnhorst CL]] |
| - | [[Category: Walsh, S T.R]] | + | [[Category: Walsh STR]] |
| - | [[Category: Antibody 4a10 fab fragment]]
| + | |
| - | [[Category: Immune system]]
| + | |
| - | [[Category: Protein polymer]]
| + | |
| Structural highlights
Publication Abstract from PubMed
Pediatric T cell acute lymphoblastic leukemia (T-ALL) cells frequently contain mutations in the interleukin-7 (IL-7) receptor pathway or respond to IL-7 itself. To target the IL-7 receptor on T-ALL cells, murine monoclonal antibodies (MAbs) were developed against the human IL-7Ralpha chain and chimerized with human IgG1 constant regions. Crystal structures demonstrate that the two MAbs bound different IL-7Ralpha epitopes. The MAbs mediated antibody-dependent cell-mediated cytotoxicity (ADCC) against patient-derived xenograft (PDX) T-ALL cells, which was improved by combining two MAbs. In vivo, the MAbs showed therapeutic efficacy via ADCC-dependent and independent mechanisms in minimal residual and established disease. PDX T-ALL cells that relapsed following a course of chemotherapy displayed elevated IL-7Ralpha, and MAb treatment is effective against relapsing disease, suggesting the use of anti-IL7Ralpha MAbs in relapsed T-ALL patients or patients that do not respond to chemotherapy.
New anti-IL-7Ralpha monoclonal antibodies show efficacy against T cell acute lymphoblastic leukemia in pre-clinical models.,Hixon JA, Andrews C, Kashi L, Kohnhorst CL, Senkevitch E, Czarra K, Barata JT, Li W, Schneider JP, Walsh STR, Durum SK Leukemia. 2019 Aug 22. pii: 10.1038/s41375-019-0531-8. doi:, 10.1038/s41375-019-0531-8. PMID:31439943[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
See Also
References
- ↑ Hixon JA, Andrews C, Kashi L, Kohnhorst CL, Senkevitch E, Czarra K, Barata JT, Li W, Schneider JP, Walsh STR, Durum SK. New anti-IL-7Ralpha monoclonal antibodies show efficacy against T cell acute lymphoblastic leukemia in pre-clinical models. Leukemia. 2019 Aug 22. pii: 10.1038/s41375-019-0531-8. doi:, 10.1038/s41375-019-0531-8. PMID:31439943 doi:http://dx.doi.org/10.1038/s41375-019-0531-8
|
